Oligonucleotide Therapy

At Frontage Laboratories, we have developed highly sensitive and specific quantitative methods to determine OGN in plasma and tissues using hybridization immunoassay and LC-MS techniques. We present the method development, validation, and comparison of these techniques for the quantification of OGN in our Gene Therapy Webinar.

Webinar: Achieving Sensitive and Specific Oligonucleotide Quantification

Gene therapy provides the hope of actual cures. These therapies still have many challenges to overcome before they will become widely developed therapeutic options. Oligonucleotide (OGN) therapy is increasingly recognized as an important therapeutic modality with the promise of curing diseases. Oligonucleotide-based therapeutics are increasingly being used for successfully treating diseases and are even considered for individualized treatments However, unlike most biotherapeutics, the development of OGN drugs often requires their determination with high sensitivity and specificity in multiple and complex biologic matrices such as blood and tissues in order to measure their exposure and distribution for understating PK, PD, and safety.

Read about our insights into cell and gene therapy for oncology.